Jyoti G Yellol

Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.

C. Janiak, P. Bednarski, Alicia Buceta, 2015, Journal of medicinal chemistry.

Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.

V. Brabec, J. Kašpárková, H. Kostrhunova, 2017, Chemistry.

On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes.

C. Janiak, V. Vasylyeva, A. Donaire, 2013, Chemical communications.

Synthesis of 2-pyridyl-benzimidazole iridium(III), ruthenium(II), and platinum(II) complexes. study of the activity as inhibitors of amyloid-β aggregation and neurotoxicity evaluation.

C. Janiak, K. Barnham, A. Donaire, 2015, Inorganic chemistry.

Highly potent extranuclear-targeted luminescent iridium(iii) antitumor agents containing benzimidazole-based ligands with a handle for functionalization.

V. Brabec, C. Janiak, S. A. Perez, 2016, Chemical communications.

A new C,N-cyclometalated osmium(ii) arene anticancer scaffold with a handle for functionalization and antioxidative properties.

C. Janiak, R. Schobert, M. Rothemund, 2018, Chemical communications.

Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.

V. Brabec, J. Kašpárková, J. Ruiz, 2017, Chemistry.